outpatient—3 months (8 physician b, 3 medicaion c)
symptomatic (untreated, initial treatment)
outpatient (same as for disseminated disease)
Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $10.8 million for a H. capsulatum vaccine.
If a vaccine program were implemented today and the vaccine were 100% efficacious and utilized by 100% of the target population, the annualized present value of the cost per QALY gained is $300,000. Using committee assumptions of less-than-ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is $600,000.
See Chapters 4 and 5 for details on the methods and assumptions used by the committee for the results reported.